24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Antenatal Glucocorticoid Treatment Induces Adaptations in Adult Midbrain Dopamine Neurons, which Underpin Sexually Dimorphic Behavioral Resilience

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We demonstrated previously that antenatal glucocorticoid treatment (AGT, gestational days 16–19) altered the size and organization of the adult rat midbrain dopaminergic (DA) populations. Here we investigated the consequences of these AGT-induced cytoarchitectural disturbances on indices of DA function in adult rats. We show that in adulthood, enrichment of striatal DA fiber density paralleled AGT-induced increases in the numbers of midbrain DA neurons, which retained normal basal electrophysiological properties. This was co-incident with changes in (i) striatal D 2-type receptor levels (increased, both sexes); (ii) D 1-type receptor levels (males decreased; females increased); (iii) DA transporter levels (males increased; females decreased) in striatal regions; and (iv) amphetamine-induced mesolimbic DA release (males increased; females decreased). However, despite these profound, sexually dimorphic changes in markers of DA neurotransmission, in-utero glucocorticoid overexposure had a modest or no effect on a range of conditioned and unconditioned appetitive behaviors known to depend on mesolimbic DA activity. These findings provide empirical evidence for enduring AGT-induced adaptive mechanisms within the midbrain DA circuitry, which preserve some, but not all, functions, thereby casting further light on the vulnerability of these systems to environmental perturbations. Furthermore, they demonstrate these effects are achieved by different, often opponent, adaptive mechanisms in males and females, with translational implications for sex biases commonly found in midbrain DA-associated disorders.

          Related collections

          Most cited references51

          • Record: found
          • Abstract: found
          • Article: not found

          Epidemiology of women and depression.

          R Kessler (2003)
          Depression is the leading cause of disease-related disability among women in the world today. Depression is much more common among women than men, with female/male risk ratios roughly 2:1. Recent epidemiological research is reviewed. Implications are suggested for needed future research. The higher prevalence of depression among women than men is due to higher risk of first onset, not to differential persistence or recurrence. Although the gender difference first emerges in puberty, other experiences related to changes in sex hormones (pregnancy, menopause, use of oral contraceptives, and use of hormone replacement therapy) do not significantly influence major depression. These observations suggest that the key to understanding the higher rates of depression among women than men lies in an investigation of the joint effects of biological vulnerabilities and environmental provoking experiences. Advancing understanding of female depression will require future epidemiologic research to focus on first onsets and to follow incident cohorts of young people through the pubertal transition into young adulthood with fine-grained measures of both sex hormones and gender-related environmental experiences. Experimental interventions aimed at primary prevention by jointly manipulating putative biological and environmental risk factors will likely be needed to adjudicate between contending causal hypotheses regarding the separate and joint effects of interrelated risk factors.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines.

            The classic view of estrogen actions in the brain was confined to regulation of ovulation and reproductive behavior in the female of all mammalian species studied, including humans. Burgeoning evidence now documents profound effects of estrogens on learning, memory, and mood as well as neurodevelopmental and neurodegenerative processes. Most data derive from studies in females, but there is mounting recognition that estrogens play important roles in the male brain, where they can be generated from circulating testosterone by local aromatase enzymes or synthesized de novo by neurons and glia. Estrogen-based therapy therefore holds considerable promise for brain disorders that affect both men and women. However, as investigations are beginning to consider the role of estrogens in the male brain more carefully, it emerges that they have different, even opposite, effects as well as similar effects in male and female brains. This review focuses on these differences, including sex dimorphisms in the ability of estradiol to influence synaptic plasticity, neurotransmission, neurodegeneration, and cognition, which, we argue, are due in a large part to sex differences in the organization of the underlying circuitry. There are notable sex differences in the incidence and manifestations of virtually all central nervous system disorders, including neurodegenerative disease (Parkinson's and Alzheimer's), drug abuse, anxiety, and depression. Understanding the cellular and molecular basis of sex differences in brain physiology and responses to estrogen and estrogen mimics is, therefore, vitally important for understanding the nature and origins of sex-specific pathological conditions and for designing novel hormone-based therapeutic agents that will have optimal effectiveness in men or women.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mechanisms of disease: glucocorticoids, their placental metabolism and fetal 'programming' of adult pathophysiology.

              Epidemiological evidence suggests that an adverse prenatal environment permanently 'programs' physiology and increases the risk of cardiovascular, metabolic, neuroendocrine and psychiatric disorders in adulthood. Prenatal stress or exposure to excess glucocorticoids might provide the link between fetal maturation and adult pathophysiology. In a variety of animal models, prenatal stress, glucocorticoid exposure and inhibition (or knockout of) 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2)--the fetoplacental barrier to maternal glucocorticoids--reduce birth weight and cause increases in adult blood pressure, glucose levels, hypothalamic-pituitary-adrenal (HPA) axis activity and anxiety-related behaviors. In humans, mutations in the gene that encodes 11beta- hydroxysteroid dehydrogenase type 2 are associated with low birth weight. Babies with low birth weight have higher plasma cortisol levels throughout life, which indicates HPA-axis programming. In human pregnancy, severe maternal stress affects the offspring's HPA axis and is associated with neuropsychiatric disorders; moreover, maternal glucocorticoid therapy alters offspring brain function. The molecular mechanisms that underlie prenatal programming might reflect permanent changes in the expression of specific transcription factors, including the glucocorticoid receptor; tissue specific effects reflect modification of one or more of the multiple alternative first exons or promoters of the glucocorticoid receptor gene. Intriguingly, some of these effects seem to be inherited by subsequent generations that are unexposed to exogenous glucocorticoids at any point in their lifespan from fertilization, which implies that these epigenetic effects persist.
                Bookmark

                Author and article information

                Journal
                Neuropsychopharmacology
                Neuropsychopharmacology
                Neuropsychopharmacology
                Nature Publishing Group
                0893-133X
                1740-634X
                January 2014
                09 August 2013
                11 September 2013
                1 January 2014
                : 39
                : 2
                : 339-350
                Affiliations
                [1 ]Behavioral and Clinical Neuroscience Institute, University of Cambridge , Cambridge, UK
                [2 ]Department of Psychology, University of Cambridge , Cambridge, UK
                [3 ]Division of Brain Sciences, Imperial College London, Hammersmith Hospital , London, UK
                [4 ]MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital , London, UK
                [5 ]Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital , Cambridge, UK
                Author notes
                [* ]Division of Brain Sciences, Imperial College London, Hammersmith Hospital , Du Cane Road, London W12 0NN, UK, Tel: +44 (0) 20 8383 8037, Fax: +44 (0) 20 8383 8032, E-mail: g.gillies@ 123456imperial.ac.uk
                [6]

                These authors contributed equally to this work.

                [7]

                Current address: William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Charterhouse Square, London EC1 6BQ, UK.

                [8]

                Current address: Physiopathology of the Neuronal Network Responsible for the Sleep-Waking Cycle Team, CNRS UMR5292; INSERM U1028; Lyon Neuroscience Research Center, Lyon F-69372, France.

                [9]

                These authors are the joint senior authors.

                Article
                npp2013196
                10.1038/npp.2013.196
                3870772
                23929547
                1c3ccdf0-de65-4195-a3b2-91f18c795620
                Copyright © 2014 American College of Neuropsychopharmacology

                This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

                History
                : 19 February 2013
                : 11 July 2013
                : 01 August 2013
                Categories
                Original Article

                Pharmacology & Pharmaceutical medicine
                dopamine,glucocorticoids,neuroendocrinology,programming,sex differences,antenatal,behavioral science,psychopharmacology,antenatal glucocorticoid treatment,dexamethasone,dopamine-dependent behaviors,midbrain dopaminergic systems

                Comments

                Comment on this article